Skip to Main Content

Author Details

Sameer A Parikh
Mayo Clinic
2010
139
33
PMIDPaper TitleJournal TitlePublished Year
37879074CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS.Blood2024
36503412Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection.Leuk Lymphoma2023
37859995Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis.Mayo Clin Proc Innov Qual Outcomes2023
37614209Safety of radiotherapy for second primary malignancies in patients with chronic lymphocytic leukemia receiving concurrent novel agent treatment.Am J Hematol2023
37212419Impact of type 2 diabetes on mortality, cause of death, and treatment in chronic lymphocytic leukemia.Am J Hematol2023
37147423Relationship among three common hematological premalignant conditions.Leukemia2023
37414216Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia.Ann Oncol2023
37378662AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells.Cancer Immunol Res2023
37294394Richter Transformation of Chronic Lymphocytic Leukemia-Are We Making Progress?Curr Hematol Malig Rep2023
36624313Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome.Nat Med2023
36691752BTKi bonanza in CLL/SLL: Sorting out the differences.Am J Hematol2023
36877634Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL.Blood Adv2023
36908110Functional humoral and cellular response of monovalent COVID-19-vaccines against Omicron BA.2 variant of SARS-CoV-2 in patients with chronic lymphocytic leukemia.Leuk Lymphoma2023
34285341Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans.Leukemia2022
35841338Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia.Br J Haematol2022
35440691GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity.Leukemia2022
35525334Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia.Exp Hematol2022
35421421Aberrant expression of lymphoid enhancer-binding factor 1 in Hodgkin lymphoma.Hum Pathol2022
35778390B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells.Blood Cancer J2022
36446777Chronic lymphocytic leukemia treatment algorithm 2022.Blood Cancer J2022
36543762Correction: Chronic lymphocytic leukemia treatment algorithm 2022.Blood Cancer J2022
36509740Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia.Blood Cancer J2022
36418344The risk of coronavirus disease 2019 (COVID-19) among individuals with monoclonal B cell lymphocytosis.Blood Cancer J2022
35969843Progression and survival of MBL: a screening study of 10â¿¿139 individuals.Blood2022
36070610Development of a distributed international patient data registry for hairy cell leukemia.Leuk Lymphoma2022
36202790Fatal Powassan virus encephalitis in patients with chronic lymphocytic leukemia.Blood Cancer J2022
36156121Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19.Blood Adv2022
36050317Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib.Blood Cancer J2022
35151528CLL update 2022: A continuing evolution in care.Blood Rev2022
35091549Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?Blood Cancer J2022
35090171Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma.Blood2022
35108473Calm before the Storm.N Engl J Med2022
34929063A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia.Am J Hematol2022
35169244Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis.Leukemia2022
35194022Isolated anemia in patients with large granular lymphocytic leukemia (LGLL).Blood Cancer J2022
34699616Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis.Am J Hematol2022
34806797Differential transcriptomic profiling in ibrutinib-naïve versus ibrutinib-resistant Richter syndrome.Hematol Oncol2022
34677833Hiding in (not so) plain sight: Spontaneous tumor Lysis syndrome due to intravascular large B cell lymphoma.Am J Hematol2022
32488603Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.Ann Hematol2021
33602892Upregulation of AXL and β-catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance.Blood Cancer J2021
33654067Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia.Blood Cancer J2021
33876228The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL.Blood2021
33596191Early intervention in asymptomatic chronic lymphocytic leukemia.Clin Adv Hematol Oncol2021
33512457Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families.Blood2021
33507295Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair.Blood2021
33749852The prognostic significance of del6q23 in chronic lymphocytic leukemia.Am J Hematol2021
34244299Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity.Cancer Immunol Res2021
33947938Hairy cell leukemia and COVID-19 adaptation of treatment guidelines.Leukemia2021
33972504Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome.Blood Cancer J2021
34354039Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index.Blood Cancer J2021
  • 1 - 50 of 139

Recommended Authors

Jessica Leonard
Oregon Health & Science University
Career Start Year 2015
Number of shared co-authors 1
Zhengming Chen
Weill Cornell Medicine and New York Presbyterian Hospital
Career Start Year 2013
Number of shared co-authors 0
Shalin Kothari
Yale University
Career Start Year 2013
Number of shared co-authors 0
Panagiotis Baliakas
Uppsala University
Career Start Year 2012
Number of shared co-authors 4
Srinivas K Tantravahi
Huntsman Cancer Institute at the University of Utah.
Career Start Year 2012
Number of shared co-authors 2
Gareth P Gregory
School of Clinical Sciences at Monash Health, Monash University
Career Start Year 2011
Number of shared co-authors 0
David Wu
University of Washington
Career Start Year 2010
Number of shared co-authors 3
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
Milos D Miljkovic
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 2009
Number of shared co-authors 1
Uma Borate
The Ohio State University
Career Start Year 2008
Number of shared co-authors 5
Amanda Winters
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 0
Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 5
Geoffrey Shouse
City of Hope National Medical Center
Career Start Year 2007
Number of shared co-authors 1
Stephen E Spurgeon
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 2006
Number of shared co-authors 1
Rashmi Kanagal-Shamanna
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 4
Marlise R Luskin
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 4
Tara L Lin
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 3
Ronan Swords
Oregon Health and Science University
Career Start Year 2004
Number of shared co-authors 8
Susan Geyer
Division of Clinical Trials and Biostatistics, Mayo Clinic
Career Start Year 2001
Number of shared co-authors 6
Guang Fan
Oregon Health and Science University
Career Start Year 2000
Number of shared co-authors 1
Sze Fai Yip
Tuen Mun Hospital
Career Start Year 1999
Number of shared co-authors 0
Andrew M Evens
Rutgers Robert Wood Johnson Medical School
Career Start Year 1998
Number of shared co-authors 3
David M Weinstock
Merck & Co.
Career Start Year 1998
Number of shared co-authors 6
Eric Tse
School of Clinical Medicine, University of Hong Kong
Career Start Year 1997
Number of shared co-authors 2
Bruno C Medeiros
AbbVie Inc.
Career Start Year 1996
Number of shared co-authors 7
David A Rizzieri
Duke University Medical Center
Career Start Year 1995
Number of shared co-authors 6
Bijal Shah
Moffitt Cancer Center
Career Start Year 1992
Number of shared co-authors 2
Daniel J DeAngelo
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 9
Maryalice Stetler-Stevenson
National Cancer Institute, National Institutes of Health
Career Start Year 1981
Number of shared co-authors 6
Ulrich D??hrsen
University Hospital Essen, University of Duisburg-Essen
Career Start Year 1979
Number of shared co-authors 1

Collaborators

Tait D Shanafelt
Stanford Cancer Institute, Stanford University
Co-authored papers 49
Janet E Olson
Mayo Clinic
Co-authored papers 6
Ismail Can
Mayo Clinic
Co-authored papers 6
Robin Fo??
Sapienza University.
Co-authored papers 6
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Co-authored papers 5
Martin S Tallman
Memorial Sloan-Kettering Cancer Center
Co-authored papers 4
Robert J Kreitman
National Cancer Institute
Co-authored papers 4
Shulan Tian
Co-authored papers 4
Farhad Ravandi
University of Texas M.D. Anderson Cancer Center
Co-authored papers 4
Thomas J Kipps
University of California San Diego
Co-authored papers 3
Melissa C Larson
Mayo Clinic
Co-authored papers 3
Laura Z Rassenti
University of California San Diego
Co-authored papers 3
Aneel A Ashrani
Co-authored papers 2
Michael J Joyner
Mayo Clinic
Co-authored papers 2
Jeffrey L Winters
Mayo Clinic
Co-authored papers 2
Jennifer A Whitaker
Co-authored papers 2
Justin E Juskewitch
Mayo Clinic
Co-authored papers 2
Ravindra Ganesh
Mayo Clinic
Co-authored papers 2
Jorge Cortes
Georgia Cancer Center
Co-authored papers 2
Sundararajan Vincent Rajkumar
Co-authored papers 2
Jonathon W Senefeld
University of Illinois at Urbana-Champaign
Co-authored papers 2
Elitza S Theel
Division of Clinical Microbiology, Mayo Clinic
Co-authored papers 2
Arturo Casadevall
Johns Hopkins Bloomberg School of Public Health
Co-authored papers 1
Juan G Ripoll
Mayo Clinic
Co-authored papers 1
Naseema Gangat
Mayo Clinic
Co-authored papers 1
James R Stubbs
Mayo Clinic
Co-authored papers 1
Stephen A Klassen
Brock University
Co-authored papers 1
Nigel Paneth
College of Human Medicine, Michigan State University
Co-authored papers 1
Kathryn F Larson
Mayo Clinic
Co-authored papers 1
Alexander J Lazar
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
Release 1.2